Laurenz Govaerts joined LSP in 2021 as an analyst. In his current position he is part of the LSP investment team focused on unlisted equities and is involved in all stages of the investment process. His primary role is in initial deal flow screening, and in-depth scientific and clinical due diligence on investment opportunities for their future potential.
Prior to joining LSP, Laurenz was a doctoral researcher at KU Leuven and Vlerick Business School for five years. Besides his doctoral research, Laurenz was involved in consulting projects for Vlerick Business School’s life science clients and teached in multiple master programs at both KU Leuven and Vlerick Business School.
Laurenz is in the final stages of his PhD, which he conducts under the supervision of Professor Steven Simoens (KU Leuven), Professor Isabelle Huys (KU Leuven) and Professor Walter Van Dyck (Vlerick Business School). His research is focussed on the valuation and evaluation of precision medicines. For his research, Laurenz obtained a personal scholarship from the Flemish Research Institute (FWO) and directly gathered funds from six pharmaceutical companies under the PROMISE Fund of KU Leuven. Laurenz has multiple publications in the health technology assessment and health economics domain (e.g. Value in Health & Journal of Technology Assessment in Healthcare).
During his studies Laurenz resided one year in Munich as a protein engineer at Roche, and in Bilbao at the Basque Institute of Health Innovation as a visiting scholar under a Marie-Curie scholarship. Laurenz has a Master in Drug Development (M.Sc.) and a Master in Health Policy and Management (M.Sc.) from KU Leuven.